SCHEMBL5217810

SCHEMBL5217810

COC(=O)c1cc(NS(=O)(=O)CCCCl)cc(SC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.41
ALDH1A1 P00352 8/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
HTT P42858 2/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
KDM4E B2RXH2 3/20 0.38
POLB P06746 1/20 0.36
LMNA P02545 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA7 P43166 2/20 0.33
CA9 Q16790 2/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13229561 0.88 HPGD (0.48) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL13326134 0.84 HPGD (0.47) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5217087 0.82 HPGD (0.46) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5218399 0.81 HPGD (0.44) HPGDALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5217953 0.81 HPGD (0.41) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5218226 0.79 HPGD (0.44) HPGDALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL5224471 0.79 POLB (0.47) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5219349 0.78 MAPT (0.47) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5223441 0.77 HPGD (0.40) HPGDALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL5217234 0.75 AR (0.53) HPGDSMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253198-B2 Hydroxyethylamine derivatives for the treatment of Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-08-07 US disclosed
EP-1567488-B1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LTD (GB) 2007-02-21 EP disclosed
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-02-02 US disclosed
EP-1567488-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
WO-2004050619-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease BACE2, PSEN2, BACE1 HPGD 2131/4885ALDH1A1 3102/4885MAPT 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.